Bioporto ASTHOXF 66 Net Current Asset Value is $0.02 as of Dec. 2025, which is 100% below its 10-year median of 12.15. GuruFocus rates THOXF with a GF Score™ of 66/100 and a GF Value™ of $0.17. The stock has 3 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, Bioporto AS ranks worse than 74.49% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Bioporto AS's net current asset value per share for the quarter that ended in Dec. 2025 was $0.02.
The historical rank and industry rank for Bioporto AS's Net Current Asset Value or its related term are showing as below:
THOXF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 7.25 Med: 12.15 Max: 29.09
Current: 14.9
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Bioporto AS was 29.09. The lowest was 7.25. And the median was 12.15.
THOXF's Price-to-Net-Current-Asset-Value is ranked worse than 74.49% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.96
vs THOXF: 14.90
Bioporto AS (OTCPK:THOXF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Bioporto AS Net Current Asset Value Related Terms
Bioporto AS Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Bioporto AS's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
THOXF vs TMO, DHR, IDXX: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, Bioporto AS's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioporto AS Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Bioporto AS's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.02 mean?
Bioporto AS (THOXF) has a Net Current Asset Value of $0.02 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Bioporto AS and its competitors. This is 100% below median its historical median of 12.15. Over the past decade, Bioporto AS's Net Current Asset Value has ranged from 7.25 to 29.09. According to the industry distribution chart, Bioporto AS ranks #73 out of 98 companies in the Medical Diagnostics & Research industry, placing it in the top 74.5%.
Is Bioporto AS's Net Current Asset Value too high?
Bioporto AS's current Net Current Asset Value of $0.02 is 100% below median its 10-year median of 12.15. Over the past 10 years, this metric has ranged from a low of 7.25 to a high of 29.09. The Medical Diagnostics & Research industry median Net Current Asset Value is 3.96. Bioporto AS's value of $0.02 is 99.5% below this industry median. Based on the distribution chart, Bioporto AS ranks #73 out of 98 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Bioporto AS has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Bioporto AS's Net Current Asset Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bioporto AS ranks #73 out of 98 companies for Net Current Asset Value. This places Bioporto AS in the lower half of its industry. The industry median Net Current Asset Value is 3.96. Bioporto AS's value of $0.02 is 99.5% below this benchmark. Historically, Bioporto AS's own Net Current Asset Value has ranged from 7.25 to 29.09 over the past decade. While the company's 10-year median is 12.15 vs. the industry median of 3.96, Bioporto AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 3.96, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bioporto AS's current Net Current Asset Value of $0.02 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Bioporto AS and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 3.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bioporto AS's current Net Current Asset Value is $0.02, which is 100% below median its own 10-year median of 12.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioporto AS stock overvalued right now?
Bioporto AS (THOXF) has a current Net Current Asset Value of $0.02. The stock's GF Value™ is $0.17, compared to a current price of $0.15 — trading 12.4% below its estimated fair value. The current Net Current Asset Value is $0.02, which is 100% below median its 10-year median of 12.15 and 99.5% below the Medical Diagnostics & Research industry median of 3.96. Bioporto AS's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Bioporto AS (THOXF), the current Net Current Asset Value is $0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bioporto AS (THOXF) Overvalued in 2026?
Based on GuruFocus' analysis, Bioporto AS stock appears to be undervalued.
The current stock price of $0.15 is trading 12.4% below its estimated GF Value™ of $0.17.
Key valuation signals for THOXF:
Net Current Asset Value: $0.02 (100% below median its 10-year median of 12.15)
GF Value™: $0.17 vs. price of $0.15 (12.4% below fair value)
Industry Position: 99.5% below the Medical Diagnostics & Research median (#73 of 98)
No single metric tells the full story. See the THOXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America. Geographically, its business area is in North America, Denmark, and rest of Europe, and Asia. The products of the company involve: ProNephro AKI, The NGAL Test, Antibodies, ELISA Kits, gRad Lateral Flow, and others.
66GF Score
Get the complete analysis for THOXF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
THOXF has been successfully added to your 
